Commitments and Contingencies (Details Narrative) - USD ($)
|
|
|
|
|
|
|
|
2 Months Ended |
3 Months Ended |
|
Apr. 09, 2021 |
Aug. 12, 2020 |
Sep. 12, 2018 |
Aug. 20, 2018 |
Mar. 22, 2018 |
Sep. 14, 2015 |
Dec. 24, 2013 |
Aug. 31, 2020 |
Mar. 31, 2022 |
Mar. 31, 2021 |
Dec. 31, 2021 |
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Contractual commitment |
|
|
|
|
|
|
|
|
$ 8,399,000
|
|
|
Research and development costs |
|
|
|
|
|
|
|
|
458,450
|
$ 443,526
|
|
City of Hope [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
307,000
|
|
|
GEIS [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Amount related to milestone payment |
|
|
|
|
|
|
|
|
67,582
|
|
|
NDA Consulting Corp [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Consulting and advisory fee |
|
|
|
|
|
|
$ 4,000
|
|
4,000
|
4,000
|
|
Clinical Trial Research Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Advance amount related to milestone payment |
|
|
|
|
|
|
|
|
3,332
|
7,384
|
|
Research and development costs |
|
|
|
|
|
|
|
|
$ 108,009
|
|
|
Aggregate commitments expected, description |
|
|
|
|
|
|
|
|
The Company’s aggregate commitment pursuant to
this agreement, less amounts previously paid to date, totaled approximately $600,000 as of March 31, 2022, which is expected to be incurred
through December 31, 2025
|
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
$ 600,000
|
|
|
Collaboration Agreement [Member] | GEIS [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Advance amount related to milestone payment |
|
|
|
|
|
|
|
|
0
|
24,171
|
|
Research and development costs |
|
|
|
|
|
|
|
|
$ 155,053
|
|
|
Aggregate commitments expected, description |
|
|
|
|
|
|
|
|
The Company’s aggregate commitment pursuant to
this agreement, less amounts previously paid to date, totaled approximately $4,166,000 as of March 31, 2022, which is expected to be
incurred through December 31, 2025
|
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
$ 4,166,000
|
|
|
Collaboration Agreement [Member] | BioPharmaWorks LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Consulting and advisory fee |
|
|
|
|
|
$ 10,000
|
|
|
|
|
|
Reimbursed expense |
|
|
|
|
|
|
|
|
30,000
|
30,000
|
|
Development Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
|
|
|
|
|
|
$ 292,293
|
|
|
Aggregate commitments expected, description |
|
|
|
|
|
|
|
|
The Company’s aggregate commitment pursuant to this agreement,
less amounts previously paid to date, totaled approximately $29,000 as of March 31, 2022, which is expected to be incurred through June
30, 2022
|
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
$ 29,000
|
|
|
Other Clinical Agreements [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
|
|
|
|
|
|
1,153,000
|
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
206,000
|
|
|
Clinical Research Support Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
800,000
|
|
|
Clinical Research Support Agreement [Member] | City of Hope [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
|
|
|
|
|
|
0
|
240,508
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
2,433,000
|
|
|
Work Order Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
|
|
|
|
|
|
95,166
|
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
864,000
|
|
|
Work Order Agreement [Member] | City of Hope [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Advance amount related to milestone payment |
|
|
|
|
|
|
|
|
4,500
|
3,540
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
29,126
|
|
|
Work Order Agreement [Member] | Theradex Systems, Inc. [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
$ 954,000
|
|
|
|
|
|
3,281
|
941
|
|
Material Transfer Agreement [Member] | INSERM [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
0
|
|
$ 0
|
Material Transfer Agreement [Member] | INSERM [Member] | Development Milestones [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Milestone payments |
|
|
|
|
$ 1,750,000
|
|
|
|
|
|
|
Material Transfer Agreement [Member] | INSERM [Member] | Commercial Milestones [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Milestone payments |
|
|
|
|
$ 6,500,000
|
|
|
|
|
|
|
Exclusive License Agreement [Member] | First Four Years [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Minimum payments for royalties |
|
|
|
|
|
|
|
|
50,000
|
|
|
Exclusive License Agreement [Member] | Five Years And Thereafter [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Minimum payments for royalties |
|
|
|
|
|
|
|
|
100,000
|
|
|
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Non-refundable license issue fee |
|
|
|
$ 25,000
|
|
|
|
|
|
|
|
Annual license maintenance fee |
|
|
|
25,000
|
|
|
|
|
|
|
|
Payments on non-refundable milestone |
|
|
|
$ 1,897,000
|
|
|
|
|
|
|
|
Amount charges to operations |
|
|
|
|
|
|
|
|
6,165
|
$ 6,164
|
|
Employment Agreement [Member] | Executive Officers [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Salary and Wage, Excluding Cost of Good and Service Sold |
|
|
|
|
|
|
|
$ 640,000
|
|
|
|
Agreement term description |
|
|
|
|
|
|
|
one-year
period
|
|
|
|
Employment Agreement [Member] | Dr.James [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Annual compensation |
$ 775,000
|
|
|
|
|
|
|
|
|
|
|
Master Service Agreement [Member] | Foundation for Angelman Syndrome Therapy [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Percentage of proceeds agree to pay under agreement |
|
5.00%
|
|
|
|
|
|
|
|
|
|
Maximum amount received under agreement |
|
$ 250,000
|
|
|
|
|
|
|
|
|
|
Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member] |
|
|
|
|
|
|
|
|
|
|
|
Loss Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Advance amount related to milestone payment |
|
|
|
|
|
|
|
|
54,230
|
|
|
Research and development costs |
|
|
|
|
|
|
|
|
$ 109,478
|
|
|
Aggregate commitments expected, description |
|
|
|
|
|
|
|
|
The Company’s aggregate commitment pursuant to this
collaboration agreement, less amounts previously paid to date, totaled approximately $380,000 as of March 31, 2022, which is expected
to be incurred through June 30, 2025
|
|
|
Aggregate commitments expected |
|
|
|
|
|
|
|
|
$ 380,000
|
|
|